Seattle Genetics Starts Lymphoma Trial
Luke Timmerman2/3/10
Seattle Genetics (NASDAQ: SGEN) and its partner, Millennium: The Takeda Oncology Company, said today they are starting a clinical trial of the brentuximab vedotin “empowered antibody” for patients newly diagnosed with Hodgkin’s disease. The drug has been shown effective in a small study for patients with relapsed forms of Hodgkin’s, and is currently being tested in a pivotal study among that sicker patient group. The new study among newly diagnosed patients will enroll about 40 people at multiple sites in the North America. Patients will get the experimental treatment in combination with a common chemotherapy regimen.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
